secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001404644-24-000049
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene's NGN-401 gene therapy well tolerated in first three Rett syndrome patients; no overexpression toxicity
--------------------------------------------------------------------------------

- All three pediatric patients (ages 4-7) treated with single ICV dose show mild, transient AEs; no serious adverse events.
- No signs of MeCP2 overexpression toxicity in any patient, including one with a mild variant predicted to retain residual MeCP2 expression.
- Follow-up ranges from ~3 to ~9 months; data cut-off April 19, 2024.
- Interim efficacy data from Cohort 1 expected in Q4 2024; additional data including Cohort 2 in H2 2025.
- NGN-401 uses EXACT transgene regulation technology to limit overexpression risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000049/0001404644-24-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000049/ngne-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001404644-24-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer